Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Small vessel diseases in a mechanistic perspective: Targets for Intervention Affected pathways and mechanistic exploitation for prevention of stroke and dementia

SVDs-at-target

Stroke and dementia rank among the most pressing health issues in Europe. Cerebral small vessel diseases (SVDs) have emerged as a central link between these two major co-morbidities. SVDs account for more than 30% of strokes and at least 40% of dementia cases. They encounter multiple distinct diseases that can be separated based on their underlying...

Funding Programme
EU-H2020
Start Date
End Date
Total Funding
€ 5 998 300
European Countries Involved

Structural and biophysical characterisation of insulin receptor and glutamate receptors AMPAR and NMDAR in complex with SorCS coreceptors 1 and 2

SorCS

Type II diabetes (T2D), Alzheimer’s Disease (AD) and Parkinson’s disease (PD) are common age-related diseases, which have reached endemic levels and become a burden for the global health. Lifestyle and environment are risk factors, but cannot explain all cases - genes also predispose for these diseases. Common for T2D, AD and PD is abnormal cell...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 214 934
European Countries Involved

Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

2D-BioPAD

2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 5 957 949
European Countries Involved

Synaptic dysfunction in Neurodegenerative Diseases

SYNDEGEN

Neurodegenerative diseases (NDDs) of aging are a growing burden on societies. Although studies on the degeneration of neurons have been a main focus of research, increasing evidence points to synapses as the site where Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) begin. There is growing evidence that synapses are...

Funding Programme
EU-H2020
Start Date
End Date
Total Funding
€ 3 129 428
European Countries Involved

Twinning for excellence in biophysics of protein interactions and self-assembly

TWIN2PIPSA

TWIN2PIPSA will improve R&I capacities of FC.ID/ULisboa (Portugal) in the field of protein folding biophysics and conformational diseases by partnering in joint Twinning activities with three world-leading research and technological development performers: the University of Cambridge (UCAM), the University of Copenhagen (UCPH), and Tel Aviv...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 1 228 957
European Countries Involved

Twinning for Excellence in Research, Training and Innovation in Protein Misfolding Diseases

Twin4Promis

Protein misfolding diseases (PMDs) are a large group of human disorders caused by protein misfolding and include serious conditions with high socio-economic impact, such as Alzheimer’s disease, systemic amyloidosis, obesity, cystic fibrosis, retinitis pigmentosa and type 2 diabetes. The vast majority of them remain incurable so there is currently a...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 1 201 375
European Countries Involved

Unraveling Bilobalide Biosynthesis for Sustainable and Scalable Production in Yeast

Biloba.bio

Ginkgo biloba extracts are among the most widely used plant-based health supplements in the United States and Europe. However, increasing demand has led to unsustainable overharvesting, resulting in Ginkgo biloba being classified as an endangered species. These extracts contain bioactive compounds, such as ginkgolides and bilobalide. Bilobalide, in...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 263 393
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).